Regeneron Reports Long-Term MONARCH Data for Kevzara in Rheumatoid Arthritis

Regeneron today presented long-term follow-up data from the Phase 3 MONARCH trial evaluating Kevzara (sarilumab) monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis. The data showed that Kevzara maintained significant improvements in disease activity, physical function, and quality of life over long-term treatment.